An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

Creating physiologically relevant conditions for cells that replicate in vivo environments can improve experimental results, ...

Urbanisation and a warmer climate means that more people want to swim in canals, harbours, and urban beaches. However, this means that they may swimming close to where treated wastewater and ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

From microglia reprogramming to immune cell-based diagnostics, 2025 was a big year for breakthroughs in cell biology.

Of the 11 patients treated with BE-CAR7 T cells, seven are in remission, including one patient who has been in remission for three years.

Dietary iron deficiency in mice alters lung T cell activation during influenza infection and leads to memory T cells that are ...

STEMCELL Technologies and Immudex have announced the launch of a new protocol that combines the power of the EasySep Release positive selection platform with Immudex's Dextramer® reagents, enabling ...

The flow cytometry market is expanding due to increased investment in immuno-oncology and liquid biopsy sectors. With advancements in genome-based research and single-cell analysis, flow cytometry ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune ...